Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Québec Court of Appeal Greenlights Securities Class Action on behalf of Valeant Pharmaceuticals Investors

Canada NewsWire

MONTRÉAL, Dec. 4, 2017 /CNW/ - A class action on behalf of investors in Valeant Pharmaceuticals International, Inc. ("Valeant") (TSX and NYSE: "VRX") will proceed toward trial now that Québec's Court of Appeal has dismissed applications by the defendants to commence an appeal from the judgment of the Honourable Justice Chantal Chatelain of the Québec Superior Court, dated August 29, 2017, which authorized the securities class action.

A notice detailing the impact of the authorization of the action as a class proceeding on the rights of investors will be delivered at a later date in accordance with a further order of the Court.

The class action was brought on behalf of persons who acquired the securities of Valeant outside of the U.S. between February 28, 2013 and October 26, 2015 after allegations arose that Valeant engaged in improper business and financial reporting practices, particularly within its relationships with Philidor Rx Services.  Following an internal investigation of its board of directors, Valeant identified material weaknesses in its internal controls over financial reporting, and restated certain of its previously-released financial statements.

The defendants include Valeant, certain of Valeant's former directors and officers, Valeant's auditors PricewaterhouseCoopers LLP, and a group of underwriters including Goldman Sachs, Deutsche Bank Securities, Barclays Capital, HSBC Securities, Morgan Stanley, RBC Capital Markets, Citigroup Global Markets, CIBC World Markets, Merrill Lynch, JP Morgan Securities, TD Securities, BMO Capital Markets, Mitsubishi UFJ Securities, DNB Markets, SunTrust Robinson and SMBC Nikko Securities.

"We are very pleased that this case has passed this initial hurdle and will now be able to move ahead to a determination on its merits," said Michael Robb, a partner at Siskinds LLP.  "It is of paramount importance to investors that participants in Canada's capital markets abide by their disclosure obligations to investors. One of the ways to ensure that happens is by holding them to account in the courts."    

The plaintiffs and investor class are represented by a consortium of Canadian law firms which includes Siskinds LLP, Faguy & Co, Siskinds Desmeules, Koskie Minsky LLP, Rochon Genova LLP, Strosberg Sasso Sutts LLP, Morganti Legal, and Investigation Counsel PC.

Shareholder Inquiries:

English:

En français:



Siskinds LLP

1-800-461-6166, x 2380

nicole.young@siskinds.com

Faguy & Co.

Please direct your inquiries by email to:

classactions@faguyco.com


Media Inquiries:

English:

En français:



Michael Robb 
Siskinds LLP 
Tel: (519) 660-7872  
Email: michael.robb@siskinds.com

Shawn Faguy 
Faguy & Co 
Tel: (514) 285-8055 
Email: sfaguy@faguyco.com

 

SOURCE Siskinds LLP

View original content: http://www.newswire.ca/en/releases/archive/December2017/04/c1583.html



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today